Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Pediatric Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1296636
This article is part of the Research Topic Pediatric CNS Tumors in Low- and Middle-Income Countries: Expanding our Understanding View all 19 articles

Survival of pediatric patients with ependymoma in a tertiary cancer center in Rio de Janeiro, Brazil

Provisionally accepted
Gabriela Oigman Gabriela Oigman 1*Yung Gonzaga Yung Gonzaga 2*Sima Ferman Sima Ferman 2*
  • 1 Hospital do Câncer I, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil
  • 2 National Cancer Institute (INCA), Rio de Janeiro, Rio de Janeiro, Brazil

The final, formatted version of the article will be published soon.

    Introduction: Ependymoma is the third most frequent central malignant nervous system tumor in pediatric age. There is scarce data in the literature on survival of these patients, especially in upper and lower middle-income countries. We aimed to describe the clinical and demographic characteristics, treatment, and outcome of pediatric patients with ependymoma admitted in a public cancer hospital.Methods: Retrospective analysis of medical records of patients with ependymoma, admitted to the Pediatric Oncology department (0-20 years) during the period of 2000-2022. Data on patient, disease characteristics and treatment were analyzed. Overall survival (OS) was calculated using the Kaplan-Meier method. Results: Seventy-two patients were evaluated, median age at diagnosis was 6,5 years (range: 1-20), 63% were male, 54% of the tumors were in the posterior fossa (PF-EPN), 45% were classified as WHO grade 3, and 68% were operated in other institutions before referral. Regarding treatment, 72% underwent radiotherapy and 33% of patients underwent chemotherapy. Almost 70% percent of the patients had relapses. The median follow-up time was 5.2 years (Range: 0,1-21,4). The OS in 5 years was 67%. Totally resected tumors had OS in 5 years of 88% (p: 0.028). Conclusion: The results achieved in this series show a survival gap between UMIC and HIC. Relapses occurred mainly in the first ten years and then reaching a plateau, with the majority of patients experiencing endocrinological and neurological sequelae.

    Keywords: childhood cancer, Ependymoma, survival analysis, low-and-middleincome country, epidemiology 2) Introduction Formatado: Não Realce Formatado: Não Realce

    Received: 18 Sep 2023; Accepted: 07 Feb 2024.

    Copyright: © 2024 Oigman, Gonzaga and Ferman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Gabriela Oigman, Hospital do Câncer I, Instituto Nacional do Câncer (INCA), Rio de Janeiro, Brazil
    Yung Gonzaga, National Cancer Institute (INCA), Rio de Janeiro, 20230-130, Rio de Janeiro, Brazil
    Sima Ferman, National Cancer Institute (INCA), Rio de Janeiro, 20230-130, Rio de Janeiro, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.